Palatin Technologies, Inc. (0KF3) Earnings Call Transcript & Summary

May 13, 2026

London Stock Exchange GB Health Care Biotechnology earnings 27 min

Earnings Call Speaker Segments

Operator

operator
#1

Good day, everyone, and welcome to the conference call on Palatin's operating results for the third quarter of fiscal year 2026. Right now, everyone is in a listen-only mode. After the formal presentation, there will be a question-and-answer session. Should you need operator assistance at any point during the conference, just press star zero on your telephone keypad. Please be advised that this conference call is being recorded. Before we get to our remarks, I want to note that statements made by Palatin that are not historical facts may constitute forward-looking statements. Such statements rest on assumptions that may or may not turn out to be accurate, and actual results could differ materially from those anticipated because of the various risks and uncertainties covered in the company's recent filings with the Securities and Exchange Commission. Please weigh such risks and uncertainties carefully when evaluating these forward-looking statements regarding Palatin's prospects. Now I'd like to hand the call over to your host, Dr. Carl Spana, Palatin's President and Chief Executive Officer. Please go ahead.

Carl Spana

executive
#2

Thanks, and good morning, everyone, and welcome to the call for Palatin's third quarter of fiscal year 2026. Dr. Carl Spana here — I serve as CEO and President of Palatin. Joining me today is Stephen Wills, who is Palatin's Chief Financial Officer and Chief Operating Officer. Earlier today, we put out a press release that reported Palatin's financial results for the third quarter of fiscal year 2026, and now we're giving a corporate update. On today's call, we'll spotlight the progress we're making in advancing our obesity pipeline built on the melanocortin 4 receptor, go over recent strategic and financial milestones, and lay out our priorities as we move through 2026, after which we'll take questions and answers. To start, I'll hand the call to Stephen for the financial and operating results. Stephen?

Stephen Wills

executive
#3

Thanks, Carl, and good day, everyone. I’ll take a quick look at the financial results for our fiscal third quarter, which ended March 31st, 2026. Let’s start with revenue. In the third quarter, we recorded $3.9 million of collaboration and license revenue, versus no revenue in the same period a year earlier. That rise was mainly tied to recognizing revenue for the upfront consideration under the Altanaspack agreement. Moving to operating expenses: total operating expenses came in at $5.5 million for the quarter, against $4.8 million in the prior-year period, which had included a $0.4 million gain on purchase commitment. The growth was chiefly due to greater compensation costs and professional fees. Cash used in operations for the quarter totaled $4.4 million, compared with $5.4 million in the prior-year period. The lower cash use in operations came mainly from collaboration and license revenue recognized in the quarter. Our net loss for the third quarter of fiscal 2026 was $1.4 million, or 37 cents per basic and diluted common share, versus a net loss of $4.8 million, or $9.13 per basic and diluted common share, in the prior-year period. That better net loss was principally tied to collaboration and license revenue recognized during the quarter.

Stephen Wills

executive
#4

Now looking at the balance sheet and where we stand on liquidity: at March 31st, 2026, Palatin held $10.2 million in cash and cash equivalents, plus roughly $2.2 million in other receivables that we expect to collect in the quarter ending June 30th, 2026. Given our present operating and development plans, along with our capacity to manage the timing of certain operating expenses, we believe the cash resources we have now and the receivables we anticipate will carry operations through June 30th, 2027. With that, I'll hand the call back to Carl. Carl?

Carl Spana

executive
#5

Thank you, Steve. During this quarter, Palatin kept moving forward with its plan of pushing ahead our melanocortin 4 receptor agonist therapies aimed at rare obesity disorders, concentrating on better tolerability, usability, and long-term outcomes within chronic treatment settings. The melanocortin 4 receptor pathway is a target that has been validated clinically and commercially. We firmly believe that what will define the coming wave of innovation is not efficacy alone, but enhancements across the overall treatment profile—especially tolerability and patient-friendly delivery that can support adherence over the long term. Against that backdrop, our objective is quite simple: to develop a best-in-class melanocortin 4 receptor agonist for treating rare, syndromic, and genetic obesity disorders. Our position is unique for reaching this, given our deep experience designing melanocortin 4 receptor selective agonists together with our recent progress in grasping how receptors and ligands interact. With rare obesity disorders—hypothalamic obesity, Prader-Willi syndrome, and Bardet-Biedl syndrome among them—patients confront severe hyperphagia, swift weight gain, and major metabolic complications. Such conditions are chronic and call for lifelong treatment, while today's therapeutic choices frequently pose difficulties for long-term use. Consequently, better tolerability and usability matter greatly for delivering meaningful, sustained outcomes to patients. Turning to an update on our obesity pipeline: our melanocortin 4 receptor agonist peptide program is built to deliver sustained efficacy, with a treatment profile optimized for high selectivity toward the melanocortin 4 receptor in once-weekly delivery.

Carl Spana

executive
#6

Our once-weekly selective peptide agonist for the melanocortin 4 receptor is still set to have an initial new drug application filed during the fourth quarter of calendar 2026, and it stands as our lead clinical asset. Within our oral small molecule program, we are moving forward next-generation oral selective melanocortin 4 receptor agonist candidates, drawing on data and learnings from earlier compounds — among them PL7737 — along with recent data from our medicinal chemistry research work and our advances in grasping detailed receptor-ligand interactions. In internal preclinical studies, our candidates show significantly improved melanocortin 4 receptor selectivity, with minimal melanocortin 1 receptor activity, and greater potency at melanocortin 4 receptor than earlier compounds. We believe this better selectivity and potency will translate into lower dosing requirements and a meaningful reduction in the potential elimination of hyperpigmentation. I want to stress how important that last point is. Hyperpigmentation is a known class effect tied to melanocortin 1 receptor activity and remains a limitation of current therapies. Our approach is specifically designed to minimize melanocortin 1 receptor off-target interactions, and the selectivity data we have supports this conclusion. Our goal is to develop best-in-class therapies with superior efficacy and long-term patient compliance. Beyond advancing our obesity programs, we continue to leverage the broader potential of our melanocortin receptor platform through strategic partnerships and business development activities.

Carl Spana

executive
#7

With Boehringer Ingelheim, our retinal disease collaboration keeps delivering non-dilutive capital, chances at milestones, and possible long-term royalty participation. Across the second half of calendar 2025, upfront and milestone payments came to €7.5 million, or roughly $8.8 million. January of 2026 also saw us finish sub-licensing PL9643 for dry eye disease to Altamira Pack Labs, with $3.8 million received as upfront consideration, and we retain eligibility for royalties and payments down the road. Beyond that, positive Phase 2 proof-of-concept results leave our PL8177 ulcerative colitis program well placed for potential partnering. What these transactions show is our strategy of drawing on the breadth of our melanocortin receptor platform to bring in non-dilutive capital, back our pipeline advancements, and create several possible long-term value drivers for shareholders. To sum up, our peptide program stays on track for an IND submission in the fourth quarter of calendar 2026. Our oral small molecule program is moving next-generation candidates forward, with better selectivity and potency, toward an IND in the first half of calendar 2027. New intellectual property has been developed by us around melanocortin 4 receptor selectivity, and we keep drawing on both our vast experience and new data to design melanocortin 4 receptor therapies offering improved selectivity and overall better treatment profiles.

Carl Spana

executive
#8

Our view is that this approach puts Palatin in position to provide differentiated, best-in-class melanocortin 4 receptor agonist therapies to patients who have substantial unmet medical needs. So with that said, we'll now take your questions.

Operator

operator
#9

Sure, we can take questions from the floor now. If you’d like to ask something or offer a comment, just press star one on your phone at this point. When you ask your question, we’d appreciate it if you’d lift your handset in case you’re on a speakerphone, so the sound quality is as good as possible. Please wait a short while as we collect questions. Our first question comes from Scott Henry at AGP. Go ahead with your question — your line is open.

Scott Henry

analyst
#10

Thanks, and good morning. To go back over PL7737, has that molecule been discontinued at this point? And if that's the case, was the reason an issue with PL7737 itself, or was it that a few of the backup compounds showed a better profile for moving forward? Thank you.

Carl Spana

executive
#11

Appreciate that question, Scott. We won't be the first one out of the gate here—what matters to us is having compounds that are truly best-in-class. The criteria we use when picking a compound, or when deciding to keep one moving through development and into the clinic, are quite rigorous. It was genuinely a multifactorial call. While we were advancing PL7737 through development, we reached a stage where, for the selectivity and the dosing we were targeting to be best-in-class, we weren't convinced that compound would get us there. On top of that, because we got funded in November of last year, we managed to move several of the backup compounds ahead quickly, and we began seeing compounds that come very close to wiping out MC1R activity entirely. Their profiles are simply emerging as better than 7737's. So we faced a choice: keep directing resources toward a compound that might not be best-in-class, or shift them to the peptide—which is extremely selective, dosed once a week, and has a truly excellent profile—and then advance a second-generation compound with a substantially better profile.

Carl Spana

executive
#12

A mix of several factors played a part. We also need to keep in mind that this is a target drawing growing interest, and competition could emerge, so when we reach the final calls on entering the clinic and committing substantial investor money, we truly want that choice to be a very rigorous one, and the compounds we advance to genuinely show a high degree of selectivity for MC4, possess excellent drug-like properties, and be simpler for patients to use, whether given orally or once weekly. Many elements fed into that call. And 7737 remains extremely valuable to the company. We've gained an enormous amount of knowledge from it. We're still assessing it, and we'll keep supporting everything we're doing.

Scott Henry

analyst
#13

Okay, so with the next-generation oral small molecule compound — should we expect a clinical game plan similar to the one you used for PL7737, in terms of evaluating hypothalamic obesity patients and also Prader-Willi?

Carl Spana

executive
#14

Yes, it should take a comparable route. My view is that both the peptides and the oral small molecules are going to find their own role in managing these patients, depending on what patients prefer, how well each works, and their side effect profiles. My expectation is that these compounds will show no MC1R activity whatsoever. They should be quite clean. To me, that represents a significant step forward. Once more, though, we must remember that this will be a crowded space, and we genuinely want to ensure we're offering the very best we can provide, drawing on the experience we've built up.

Scott Henry

analyst
#15

So, if you look at what sets your pipeline apart from the compounds that are already out there and the ones still in development, what would you say are the main characteristics that distinguish it? You've clearly brought up selectivity and hyperpigmentation. Is there anything else you'd point to?

Carl Spana

executive
#16

Absolutely. That's an important point. I believe the technologies we're using to potentially provide once-a-week peptide injections could also set us apart. I think the insight that the PK parameters of these compounds need to land them in a range where we avoid reaching drug exposure levels beyond the therapeutic windows—so we can remove or sharply lower the potential side effects seen outside of hyperpigmentation. Beyond that, in the small molecule program, we're seeking compounds that truly restrict brain penetrance, keeping them out of the CNS. A number of features are designed into these candidates that, taken together, should make them superior drugs. This isn't unusual as indications progress beyond the first approved drugs. Typically it's at the second or third one that improved compounds emerge: better drug-like characteristics, better PK parameters, greater usability for patients. That's our goal.

Scott Henry

analyst
#17

Okay, so this is sort of a last question. Obviously, your strategy has tracked a lot of what we’ve observed from Rhythm and what they’ve accomplished. How would you stack your products up against Rhythm’s, and how far behind would you say you are right now?

Carl Spana

executive
#18

Sure. As things stand with approvals, setmelanotide—or IMCIVREE—belongs to Rhythm. In my view, they've accomplished a great deal in advancing that product, broadening the indications it covers, and possibly starting to open up new markets for MC4 agonists. That compound is a first-generation peptide. Its shortcomings involve MC1R activity, and it requires a daily injection. I'm aware that a weekly injectable is in development behind it. Very little data exists. I can't speak to that. No data is available. My understanding is that data will come later this quarter. I can't speak to that. They also have a small molecule, LB melagon. Once again, that is a first-generation compound. Once again, hyperpigmentation shows up in the clinic. It's undergoing some reformulation work, and I don't know where that will end up. Hopefully they'll get it back into the clinic later this year. From where I sit, I believe we will deliver superior compounds. They'll be cleaner, they'll possess better drug-like characteristics, they'll have improved PK parameters, and they'll have an opportunity to be highly competitive, to expand, and to capture market share. That's the aim when you bring best-in-class forward, correct—to have the better compounds. As for how far behind you are, it depends on the indication, obviously—setmelanotide is approved.

Carl Spana

executive
#19

It has HO approval and approval across a range of indications. Our plan for getting there is available for you to review. In that scenario, we trail by several years. As for compounds in development, I can't say. Is it 1 year, 1.5 years? That isn't clear to me. I realize investors raise this question constantly and it does matter. We aren't terribly far behind, and the aim is to arrive with a superior candidate and a superior product. The more important consideration, I believe, is this: who will possess the compounds that genuinely help resolve this problem through better patient compliance and better patient usability while maintaining good efficacy. That is truly what you are striving to advance. In the end, that is probably what will decide this market.

Scott Henry

analyst
#20

Thanks. Appreciate you taking the questions.

Operator

operator
#21

Moving on to Yale Jen from Laidlaw & Company, who has our next question. Yale, the line is yours—please go ahead.

Yale Jen

analyst
#22

Morning, and thanks for taking the questions. Your oral compound has now been pushed out by roughly a year versus 7737. So my question for you is whether you foresee any challenges in getting that to IND-ready status next year. Is there anything specific you can mention without revealing too much on the competitive side?

Carl Spana

executive
#23

Sure. You know, any time you're working with small molecules that are orally active — like we were with 7737 — we conduct a huge number of preclinical studies on those compounds. We do that to assess their efficacy and selectivity, among other things, but really also their druggability, side-effect profiles, metabolism, and all sorts of other factors. At any stage, even with state-of-the-art software and similar tools helping us predict, and of course wet chemistry to work through all of it, you won't truly know what you've got, or how high you can dose, and so forth, until you're in animals and you've been through that process. I'd describe it this way: we have a very solid grasp of what's needed. I believe we understand the pharmacophores we're working with quite well. They're highly druggable, including as far as their interactions with CYPs, metabolism, and so forth go. We're highly confident that we can deliver a compound. But until we complete the work, I can't say what the actual outcome will be. I'm confident we'll do the work. We'll move the candidate forward.

Carl Spana

executive
#24

We will take the candidate through the process. I’m confident it will pass and will have a great profile. Until it’s done, I can’t comment. I don’t know.

Yale Jen

analyst
#25

Okay, that makes sense, and I appreciate the detail. I won't ask you to say too much, but how should I frame it — is this moving toward an animal study, or is it in an animal study at this point?

Carl Spana

executive
#26

Which one? We haven't settled on a final pick — it hinges on the candidate. A few of them are in animal studies, and a few are somewhat earlier than that. Later on in the year, we'll settle on the actual candidate we intend to move forward with. It differs from candidate to candidate.

Yale Jen

analyst
#27

Okay. Perhaps one final question: regarding the weekly peptides for sub-Q, I believed last time that we thought you might begin in the third quarter, but I suppose it has been pushed a bit more into the fourth. Were there any problems that you want to resolve? It seems this, as you mentioned, will be the IND-enabling path forward.

Carl Spana

executive
#28

No, there aren't any problems. Look, it's not like we're making screws here. What we do is very complex. Once again, we want to be certain we've got the correct compound. Something we're noticing is that the funding we raised in Q3 or Q4 of last year genuinely let us speed up considerably a great deal of the work underway on the medicinal chemistry front, with the peptides and the small molecules alike. What we're striving to confirm is — especially with the peptide side, with the candidate we chose — that it was the finest one we have, right, rather than something merely really good, only for us to discover a month later that we have something better. It's genuinely a matter of confirming we have the right candidate. In a good way, we're highly productive in how we understand this, and the receptor, and receptor-ligand interaction, and we've truly been pushing the boundaries and figuring out how to eliminate the MC1R activity and incorporate that into these compounds. We genuinely want to be sure we select the best one. I don't honestly see much of a difference. To me, that peptide program is progressing quite well.

Carl Spana

executive
#29

We believe we've got a really strong candidate, and at this point we're moving into the IND-enabling studies. I expect that to progress and remain on schedule quite well.

Yale Jen

analyst
#30

Great. Perhaps we can fit in one final question — you brought up that you're also looking at PWS, Prader-Willi syndrome. Right now, would that rank second behind HO, or do you think you might move on PWS even sooner or earlier than that? Thanks. Yeah.

Carl Spana

executive
#31

Once again, it all comes down to resources. In my view, the two are on equal footing. Both represent strong commercial opportunities. Each is an area with a very substantial unmet medical need for novel therapies. If we had the resources, we would prefer to advance both at the same time.

Yale Jen

analyst
#32

Great. Thank you very much, and best of luck with everything.

Carl Spana

executive
#33

Thank you.

Operator

operator
#34

We’ll now take the next question from Dev Prasad at Loop Capital. Please go ahead with your question—your line is open.

Dev Prasad

analyst
#35

Hey everyone, and thanks for taking our question. We’ve got a few. First, when it comes to the new oral compound, is the aim to get rid of hyperpigmentation completely, or are you trying to lower how often it happens and how severe it is? As a follow-up, which preclinical species or model is the most predictive for this MC1R-mediated hyperpigmentation? Then, on the once-weekly injectable, I’m just wondering what the main IND-enabling studies are that still need to be done before the planned 4Q IND submission? Thank you.

Carl Spana

executive
#36

Okay, that's a lot to cover. Let's walk through it. With the small molecule, we believe there's a chance to fully get rid of the activity. That isn't to say that once you begin chronic treatment you won't observe a modest amount, but that really is the objective, and it's what we're observing preclinically. There is a very meaningful gap between 1 and 4, but you won't know until you're in the clinic. If you consider a rat, a dog, or a mouse, their skin isn't truly pigmented, so you have to examine fur. You look at fur darkening, and there are numerous models available for that. If your compounds have strong MC1R activity and they perform in these models, that will translate to humans. We believe predictability is high, and if you're demonstrating a lack of efficacy or very large separations between where weight loss appears and where there's potential for even a minor pigmentation change, that will translate to the human condition too. As for where we stand in development, at present we're starting the IND-enabling studies. That will involve a whole set of in vitro assays we were required to conduct concerning CYP binding, metabolism, and so forth, along with getting into the animal work, which will begin as well.

Carl Spana

executive
#37

Everything is progressing and falling into place, which means we'll have the documentation required for our FDA submission and will be able to open an IND during the fourth quarter of the year.

Dev Prasad

analyst
#38

Thanks — that's great.

Operator

operator
#39

That brings us to the end of the question queue. At this point, I'll hand things back to Carl Spana for any closing remarks.

Carl Spana

executive
#40

I want to thank everybody for joining us on this call. This gives us a chance to share some updates, and we're pretty excited about where we stand and where we're headed. I appreciate the analysts' questions, since they let us go beyond what's in the script and perhaps add a bit more color and context about what we're doing. The progress we're making, I believe, is quite meaningful. We're producing some really strong IP that I think will not just support the work underway but also make things a little harder for those coming along behind us. I believe we're positioned very well and feel fairly confident about our efforts and, going forward, that we'll bring some truly phenomenal compounds into the clinic. With that, thank you, everyone. Have a great day, and we look forward to keeping everybody updated as we keep making progress on our programs. Steve?

Stephen Wills

executive
#41

Thank you as well. Enjoy the remainder of your day. Take care.

Operator

operator
#42

Thanks to all of you. That brings today's conference call to an end. At this point you're welcome to hang up your phones, and we hope the rest of your day is great. We appreciate your joining us.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Palatin Technologies, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

For developers and AI pipelines

Programmatic access to Palatin Technologies, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Palatin Technologies, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.